{
    "code": "60001081",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001081",
    "time": "2022-09-30 06:08:09",
    "許可證字號": "衛部菌疫輸字第001081號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "112\/04\/25",
    "發證日期": "107\/04\/25",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA06000108100",
    "中文品名": "沛斯博凍晶注射劑1毫克",
    "英文品名": "BESPONSA 1 mg Powder for Concentrate for Solution for infusion",
    "適應症": "Besponsa 單獨使用，適用於治療患有復發型或頑固型CD22 陽性B 細胞前驅因子之急性淋巴芽細胞白血病(ALL)之成人病患。具費城染色體陽性(Ph+)的復發型或頑固型CD22 陽性B 細胞前驅因子之ALL的成人病患，應至少對一種酪胺酸激酶抑制劑(TKI)治療無效。",
    "劑型": "243凍晶注射劑",
    "包裝": "每玻璃小瓶1毫克；100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "基因工程產品_新成分",
    "監視期限": "112\/04\/25",
    "主成分略述": "Inotuzumab Ozogamicin",
    "限制項目": "02輸　入 5F免除銜接性試驗",
    "申請商名稱": "0929101100  美商惠氏藥廠（亞洲）股份有限公司台灣分公司",
    "申請商地址": "台北市信義區松仁路100號42、43樓",
    "主製造廠": [
        {
            "製造廠名稱": "FUS0351100  WYETH PHARMACEUTICAL DIVISION OF WYETH HOLDINGS LLC",
            "製造廠廠址": "401 NORTH MIDDLETOWN ROAD, PEARL RIVER, NY 10965-1299, U.S.A.",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "原料藥及成品製造廠"
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "6605071926  久裕企業股份有限公司",
            "製造廠廠址": "桃園市桃園區大林里興邦路43巷2-1號4樓、3樓、1樓A區",
            "製造廠公司地址": "",
            "製造廠國別": "",
            "製程": "二級包裝廠(委託貼標及置入仿單)"
        },
        {
            "製造廠名稱": "FUS0196100  PHARMACIA &amp; UPJOHN COMPANY LLC",
            "製造廠廠址": "7000 Portage Road, Kalamazoo, MI, 49001, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "包裝"
        },
        {
            "製造廠名稱": "FUS0691000  WYETH BIOPHARMA DIVISION OF WYETH PHARMACEUTICALS INC",
            "製造廠廠址": "ONE BURTT ROAD, ANDOVER, MA 01810, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "原料藥製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013006800",
            "成分名稱": "Inotuzumab Ozogamicin",
            "含量描述": "",
            "含量": "1.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Besponsa_vial_appearance-107-09-20(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001081&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "2. 0524-Besponsa 1mg-Chinese Leaflet 75.5x24.7cm outline_L-110-08-18.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001081&Seq=003&Type=9"
        },
        {
            "title": "Besponsa_Carton BTL-111-04-18(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001081&Seq=005&Type=8"
        },
        {
            "title": "Besponsa_Carton BTL-110-10-04(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001081&Seq=004&Type=8"
        },
        {
            "title": "202009_Besponsa_vial_CTN_Label-109-09-29(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001081&Seq=003&Type=8"
        },
        {
            "title": "Besponsa_vial_CTN_Label-107-09-20(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001081&Seq=002&Type=8"
        },
        {
            "title": "4. 修訂後外盒-107-06-20.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001081&Seq=001&Type=8"
        }
    ]
}